OncoMatch/Clinical Trials/NCT07028125

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Is NCT07028125 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies cabozantinib and nivolumab for renal cell carcinoma (kidney cancer).

Phase 4RecruitingCentre Francois BaclesseNCT07028125Data as of May 2026

Treatment: cabozantinib and nivolumab — The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Disease stage

Metastatic disease required

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify